Despite these limitations, our study highlights that the clinically observed effect of VitD3 treatment during COVID-19 could be due, at least in part, to its suppression of NLRP3 inflammasome pathway; hence supporting its potential use as a supplement to ameliorate COVID-19 severity. The gene discussed is NLRP3; the disease is COVID-19.